Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03620058 · ClinicalTrials.gov registry record · Phase 1
CART22 Alone or in Combination With huCART19 for ALL
A Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Chemotherapy Resistant Acute Lymphoblastic Leukemia, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03620058 is a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Chemotherapy Resistant Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 23 participants, below the 44-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03620058, a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Chemotherapy Resistant Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
Conditions Studied
Interventions
- BIOLOGICAL CART22-65s cells
- BIOLOGICAL huCART19 Cells
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2036-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03620058
The ClinicalTrials.gov registry entry for NCT03620058 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (48% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which CART22-65s cells is the first listed.
NCT03620058 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03620058 about?
NCT03620058 is a clinical study titled "CART22 Alone or in Combination With huCART19 for ALL". This is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
What is the current status of trial NCT03620058?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-09-27. Estimated completion is 2036-01.
What conditions does trial NCT03620058 study?
This clinical trial studies the following conditions: Refractory Acute Lymphoblastic Leukemia, Chemotherapy Resistant Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT03620058?
The interventions under investigation include: CART22-65s cells (BIOLOGICAL), huCART19 Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03620058?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03620058 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
RECRUITING · Phase 1
-
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
RECRUITING · Phase 1
-
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
RECRUITING · Phase 1
-
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
Explore more on PlainTrial
Refractory Acute Lymphoblastic Leukemia
All registered trials for this condition
Chemotherapy Resistant Acute Lymphoblastic Leukemia
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.